NCT04955964 is a clinical trial in Angioedemas, Hereditary, sponsored by Takeda.

Who is sponsoring NCT04955964?

NCT04955964 is sponsored by Takeda.

What condition does NCT04955964 study?

NCT04955964 studies Angioedemas, Hereditary.

Is NCT04955964 still recruiting?

NCT04955964 is currently completed. Last updated 4 October 2023.

Last reviewed 2023-10-04 · How we verify

NCT04955964

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina

Completed Last updated 4 October 2023

What this trial tests

trial in Angioedemas, Hereditary in 48 participants. Completed in 7 August 2023.

Timeline

28 July 2021

Primary endpoint
7 August 2023

7 August 2023

Quick facts

Lead sponsor	Takeda
Status	Completed
Study type	OBSERVATIONAL
Enrollment	48
Start date	28 July 2021
Primary completion	7 August 2023
Estimated completion	7 August 2023
Sites	1 location across Argentina

Conditions studied

Angioedemas, Hereditary — all drugs for Angioedemas, Hereditary →

Sponsor

Takeda — full company profile →

Who can join

12 and older, any sex, with Angioedemas, Hereditary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim of this study is to learn about the safety profile of lanadelumab in teenagers and adults with hereditary angioedema (HAE) in Argentina as part of routine routine practice. This study is about collecting data only. The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study. The study will collect data from the participant's medical records. Participants do not need to visit their doctor in addition to their normal visits.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Takeda trials

Trials by the same sponsor.

NCT05669729 — A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velagluceras · not yet recruiting
NCT07403968 — A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease · Phase 2 · not yet recruiting
NCT07293364 — A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema · NA · not yet recruiting
NCT07218393 — A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt · not yet recruiting
NCT07445087 — A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04955964 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Takeda
Last refreshed: 4 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04955964.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing